

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent application of: : Group Art Unit:  
Rajiv Khanna et al. : Not Yet Known  
:  
U.S. Serial No. Not Yet Known : Examiner:  
: Not Yet Known  
:  
Filed: herewith :  
:  
International  
Application No. PCT/AU2003/001451  
:  
Int'l filing Date: November 3, 2003  
:  
For: EPSTEIN BARR VIRUS PEPTIDE :  
EPITOPES, POLYEPITOPES AND  
DELIVERY SYSTEM THEREFOR

Patrick H. Higgins, Esq.  
Registration No. 39,709  
Fox Rothschild, LLP  
P.O. Box 5231  
Princeton, NJ 08543-5231  
Tel: 609-896-7654  
Fax: 609-896-1469  
Customer No. 29880  
Deposit Account: 50-1943

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98,  
information relating to the above-identified application is hereby disclosed. Submission

of this statement is not to be construed as an admission that any of the documents submitted herewith are "material" to the examination of this application or the patentability of the invention, as the term "material" is defined in 37 C.F.R. §1.56(b), nor as any admission that the documents submitted herewith even qualify as prior art references with respect to the above-referenced patent application.


In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

To the extent there is any fee required in connection with the receipt, acceptance and/or consideration of this paper and/or any accompanying papers submitted herewith, please charge all such fees to Deposit Account 50-1943.

Respectfully submitted,

Date: May 4, 2005

  
\_\_\_\_\_  
Patrick H. Higgins  
Registration No. 39,709  
Attorney for Applicants

Fox Rothschild LLP  
P.O. Box 5231  
Princeton, NJ 08543-5231  
609-8967654  
Customer No. 29888  
e-mail: phiggins@foxrothschild.com

<b>Form PTO-1449 Modified</b>				Client Matter No. FAK-001	Serial No. <b>106533726</b> Not Yet Known	
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)				Applicant Rajiv Khanna et al.		
				Filing Date herewith	Group Not Yet Known	
U.S. Department of Commerce Patent and Trademark Office						
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initial		Document No.	Date	Country	Translation YES NO	
	AA	1999/002550 A1	01/1999	WIPO		
	AB	1229043 A1	08/2002	EP		
	AC	2002-255997	09/2002	JAPAN	X	
	AD	2001/094944 A2	12/2001	WIPO		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
	AE	LEEN A et al.: "Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses"; Journal of Virology, September 2001, p 8649-8659				
	AF	THORLEY-LAWSON D A et al.: "Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein"; Proceedings of the National Academy of Sciences of the USA (1987), 84(15), 5384-8				
	AG	O'SULLIVAN D ET AL: "Characterization of the specificity of peptide binding to four DR halotypes"; The Journal of Immunology, Vol. 145, No. 6, September 15 1990, pp1799-1808				
	AH	MEIJ P et al.: "Identification and prevalence of CD8+ T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2"; International Journal of Cancer, 26 February 2002, 99(1), 93-99				
	AI	KHANNA R et al.: "Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458				
	AJ	DURAI SWAMY J et al: "Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Converged Epitope Sequences in Virus Isolates from Diverse Geographic Regions"; Journal of Virology, July 2003, pp7401-7410				
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>		

<b>Form PTO-1449 Modified</b>		Client Matter No. FAK-001	Serial No. <b>106533726</b> Not Yet Known
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Rajiv Khanna et al.	
		Filing Date herewith	Group Not Yet Known
U.S. Department of Commerce Patent and Trademark Office			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	AK	DURAI SWAMY J et al: "Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma"; Blood, 15 April 2003, 101(8), 3150-3156	
	AL	KHANNA R et al.: "Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease"; Proceedings of the National Academy of Sciences of the USA (1999), 96(18), 10391-10396	
	AM	GENPEPT accession no AAA53227; SAMPLE J et al.: "Epstein-Barr virus types 1 and 2 have nearly identical LMP-1 transforming genes"; (& PUBMED 7931160)	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	